The Korean Journal of Applied Statistics (응용통계연구)

The Korean Statistical Society (한국통계학회)
권호 표지
DOI QR코드

DOI QR Code

Maximum tolerated dose estimation using continual reassessment method in Phase I Clinical Trial

연속재평가방법에 가속화 단계를 적용한 MTD 추정법

  • Kwon, Dohee (Department of Biomedicine.Health Science, The Catholic University of Korea) ;
  • Kim, Dongjae (Department of Biomedicine.Health Science, The Catholic University of Korea)
  • 권도희 (가톨릭대학교 의생명.건강과학과) ;
  • 김동재 (가톨릭대학교 의생명.건강과학과)
  • Received : 2019.08.22
  • Accepted : 2019.09.28
  • Published : 2019.10.31
Download PDF
⟨ Previous Next ⟩

Abstract

The purpose of a Phase I Clinical Trial is to determine the maximum tolerated dose (MTD). MTD is important because it affects subsequent clinical trials; however, the existing method has a problem due to an inadequate dose allocated to patients. In this paper, an MTD estimation method is proposed to complement the problems of the existing MTD estimation method. The suggested method applies the initial acceleration step to the modified continual reassessment method. Monte Carlo Simulation Study is adapted to compare a suggested MTD estimation method with the standard design and the modified continual reassessment method.

제1상 임상시험의 주목적은 최대허용용량(maximum tolerated dose; MTD)을 결정하는 것이다. MTD 결정을 통해 다음 임상시험에 사용될 용량이 제한되므로 투약용량 발견 시험이라고도 불리며 매우 중요한 단계이다. MTD를 결정하는 방법에는 대표적으로 DM 방법, SM 방법, CRM 방법이 있다. 본 논문에서는 기존 수정된 CRM 방법에 초기가속화 단계를 적용하여 낮은 용량에 다수의 피험자가 할당되는 문제점을 보완하는 새로운 MTD 추정 방법을 제안하였고 기존 방법들과의 비교를 위해 모의실험을 실시하였다.

Keywords

References

  1. Ahn, C. (1998). An evaluation of phaseicancer clinical trial designs, StatMed, 17, 1537-1549.
  2. Chevret, S. (1993). The continual reassessment method in cancer phase i clinical trials: a simulation study, Statistics in Medicine, 12, 1093-1108. https://doi.org/10.1002/sim.4780121201
  3. Dixon, W. and Mode, A. (1948). A method for obtaining and analyzing sensitivity data, Journal of the American Statistical Association, 43, 109-126. https://doi.org/10.1080/01621459.1948.10483254
  4. Faries, D. (1994). Practical modifications of the continual reassessment method for phase i cancer clinical trials, Journal of the Biopharmaceutical Statistics, 4, 147-164. https://doi.org/10.1080/10543409408835079
  5. Kang, S. H. (2002). Investigation on the modified continual reassessment method in phase I clinical trial, The Korean of Applied Statistics, 15, 323-336. https://doi.org/10.5351/KJAS.2002.15.2.323
  6. Korn, E., Midthune, D., Chen, T., Rubinstein, L., Christian, M., and Simon, R. (1994). A comparison of two phase I trial designs, Statistics in Medicine, 13, 1799-1806. https://doi.org/10.1002/sim.4780131802
  7. O'Quigley, J., Pepe, M., and Fisher, M. (1990). Continual reassessment method: a practical design for phase I clinical trials in cancer, Biometrics, 46, 33-48. https://doi.org/10.2307/2531628
  8. O'Quigley, J. and Shen, L. (1996). Continual reassessment method: a likelihood approach, Biometrics, 52, 163-174.
  9. Park, I. and Song, H. (1999). Estimation of maximal tolerated dose in sequential Phase I clinical trials, The Korea Communications in Statistics, 6, 543-564.
  10. Storer, B. (1989). Design and analysis of phaseiclinical trials, Biometrics, 45, 925-937. https://doi.org/10.2307/2531693